Trimetrexate: A Critical Appraisal of the Phase II Clinical Trial Experience: Evidence of Drug Discovery-Clinical Development Disjunction

References

• Marsoni S, Hoth D, Simon R. Clinical drug development: An analysis of phase II trials, 1970–1985. Cancer Treat Rep 1987; 71: 71–80
   PubMedGoogle Scholar
• Muggia FM, McGuire WP, Rozencweig M. Rationale, design, and methodology of phase II clinical trials. Methods Cancer Res 1979; 17: 199–214
   Google Scholar
• Lee YJ, Wesley RA. Statistical contributions to phase II trials in cancer: Interpretation, analysis and design. Semin Oncol 1981; 8: 403–416
   PubMed Web of Science ®Google Scholar
• Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985; 69: 1375–1381
   PubMedGoogle Scholar
• DeVita VT, Oliverio VT, Muggia FM. The drug development and clinical trials programs of the division of cancer treatment, National Cancer Institute. Cancer Clin Trials 1979; 2: 195–216
   Google Scholar
• Boyd MR. Status of the NCI preclinical amitumor drug discovery screen. Cancer: Principles and Practice of Oncology Update, vol 3, VT DeVita, Jr, S Hellman, SA Rosenberg. JB Lippincott, Philadelphia 1989; 1–12
   Google Scholar
• Elslager EF, Davoll J. Synthesis of fused pyrimidines as folate antagonists. Lectures in Heterocyclic Chemistry, RN Castle, LB Townsend, UT Orem. Hetero Corp. 1974; Vol 2: S.97–S.133
   Google Scholar
• Jackson RC, Fry DW, Boritzki TJ. Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Advances in Enzyme Regulation, vol 22, G Weber. Pergamon Press, New York 1984; 187–206
   Google Scholar
• Hamrell MR. Inhibition of dihydrofolate reductase and cell growth by antifols in a methotrexate-resistant cell line. Oncology 1984; 41: 343–348
   PubMed Web of Science ®Google Scholar
• Weir EC, Cashmore AR, Dreyer RN. Pharmacology and toxicity of a potent “nonclassical” 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs. Cancer Res 1982; 42: 1696–1702
   PubMed Web of Science ®Google Scholar
• Balis FM, Lester CM, Poplack DG. Pharmacokinetics of trimetrexate (NSC 352122) in monkeys. Cancer Res 1986; 46: 169–174
   PubMed Web of Science ®Google Scholar
• Alberts AS, Falkson G, Badat M. Trimetrexate in advanced carcinoma of the esophagus. Invest New Drugs 1988; 6: 319–321
   PubMed Web of Science ®Google Scholar
• Falkson G, Ryan LM, Haller DG. Phase II trial for the evaluation of trimetrexate in patients with inoperable squamous carcinoma of the esophagus. Am J Clin Oncol (CCT) 1992; 15: 433–435
   PubMed Web of Science ®Google Scholar
• Mauron J. Clinical response to trimetrexate as sole therapy for nonsmall cell lung cancer. Semin Oncol 1988; 15: 17–21, Suppl 2
   PubMed Web of Science ®Google Scholar
• Kris MG, D'Acquisto RW, Gralla RJ. Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer. Am J Clin Oncol (CCT) 1989; 12: 24–26
   PubMed Web of Science ®Google Scholar
• Fosella FV, Winn RJ, Holoye PY. Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma. Invest New Drugs 1992; 10: 331–335
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Yagoda A, Scher H. Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Eur J Cancer Clin Oncol 1989; 25: 753–754
   PubMedGoogle Scholar
• Witte RS, Elson P, Bryan GT. Trimetrexate in advanced renal cell carcinoma. Invest New Drugs 1992; 10: 51–54
   PubMed Web of Science ®Google Scholar
• Odujinrin O, Goldberg D, Doroshow J. Treatment of metastatic malignant melanoma with trimetrexate. A phase II study. Med Pediatr Oncol 1990; 18: 49–52
   PubMedGoogle Scholar
• Iscoe NA, Eisenhauer EA, Bodurtha AJ. Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada clinical trials group study. Invest New Drugs 1990; 8: 121–123
   PubMed Web of Science ®Google Scholar
• Carlson RW, Doroshow JH, Odujinrin OO. Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs 1990; 8: 387–389
   PubMed Web of Science ®Google Scholar
• Licht JD, Gonin R, Antman KH. Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 1991; 28: 223–225
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Wierzbicki R, Knowling M. Phase II trials of trimetrexate in advanced adult soft tissue sarcoma. Ann Oncol 1991; 2: 689–690
   PubMed Web of Science ®Google Scholar
• Weiss GR, Liu PY, O'Sullivan J. A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: A Southwest Oncology Group trial. Gynecol Oncol 1992; 45: 303–306
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Eisenhauer EA, Macdonald DR. Phase II study of trimetrexate in recurrent anaplastic glioma. Can J Neurol Sci 1990; 17: 21–23
   PubMed Web of Science ®Google Scholar
• Robert F. Trimetrexate as a single agent in patients with advanced head and neck cancer. Semin Oncol 1988; 15: 22–26, Suppl 2
   PubMed Web of Science ®Google Scholar
• Dawson NA, Costanza ME, Korzun AH. Trimetrexate in untreated and previously treated patients with metastatic breast cancer: A Cancer and Leukemia Group B study. Med Pediatr Oncol 1991; 19: 283–288
   PubMedGoogle Scholar
• Leiby JM. Trimetrexate: A phase 2 study in previously treated patients with metastatic breast cancer. Semin Oncol 1988; 15: 27–31, (Suppl 2)
   PubMed Web of Science ®Google Scholar
• Pappo A, Dubowy R, Ravindranath Y. Phase II trial of trimetrexate in the treatment of recurrent childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Natl Cancer Inst 1990; 82: 1641–1642
   PubMed Web of Science ®Google Scholar
• Takemura Y, Ohnuma T, Miyachi H. A human leukemia cell line made resistant to two folate analogues, trimetrexate and N10propargyl-5,8-dideazafolic acid (CB3717). J Cancer Res Clinical Oncol 1991; 117: 519–525
   PubMed Web of Science ®Google Scholar
• Schweitzer BI, Dicker AP, Bertino JR. Dihydrofolate reductase as a therapeutic target. FASEB J 1990; 4: 2441–2452
   PubMed Web of Science ®Google Scholar
• Li W.W., Lin JT, Tong WP. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res 1992; 52: 1434–1438
   PubMed Web of Science ®Google Scholar
• Grem JL, Ellenberg SS, King SA. Correlates of severe or life-threatening toxic effects from trimetrexate. J Natl Cancer Inst 1988; 80: 1313–1318
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Zee BC, Pater JL. Trimetrexate: Predictors of severe or life-threatening toxic effects. J Natl Cancer Inst 1988; 80: 1318–1322
   PubMed Web of Science ®Google Scholar
• Stewart JA. Safety and tolerance of trimetrexate: Results of a phase-II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists. Semin Oncol 1988; 15: 10–16, Suppl 2
   PubMed Web of Science ®Google Scholar
• Lin JT, Bertino JR. Trimetrexate: A second generation folate antagonist in clinical trial. J Clin Oncol 1987; 5: 2032–2040
   PubMed Web of Science ®Google Scholar